Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab in Recurrent Nasopharyngeal Carcinoma
NCT04376866Phase 3Recruiting
- Sponsor
- Cancer Hospital of Guangxi Medical University
- Start
- Jun 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in recurrent nasopharyngeal carcinoma, sponsored by Cancer Hospital of Guangxi Medical University. Started Jun 2020; status: recruiting.
02
Drugs
toripalimab
03
Conditions
recurrent nasopharyngeal carcinoma
Beyond the preview
Go deeper on NCT04376866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04376866.